Jeffrey A Mills1, Jeffrey R Strawn2. 1. Carl H. Lindner College of Business, University of Cincinnati, Ohio. 2. College of Medicine, University of Cincinnati, and the Cincinnati Children's Hospital Medical Center, Ohio. Electronic address: strawnjr@uc.edu.
Abstract
OBJECTIVE: To compare adverse events (AEs), suicidality, and AE-related discontinuation in double-blind, placebo-controlled trials of pediatric patients with obsessive-compulsive disorder (OCD) and anxiety disorders treated with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). METHOD: MEDLINE, PubMed, Web of Science, PsycINFO, and Embase were searched for peer-reviewed, English-language articles from inception through March 1, 2019. We identified prospective, randomized SSRI and SNRI studies in patients <18 years of age with OCD or generalized, separation, or social anxiety disorders. AE rates were extracted and medication-placebo differences were examined using Bayesian hierarchical models, then posterior estimates of relative risk (RR) were determined for each AE by medication class and disorder. RESULTS: Data were included from 18 trials (2,631 patients) and 7 medications (16 SSRI and 4 SNRI trials). Compared with placebo, SSRIs were associated with a greater likelihood of AE-related discontinuation (RR 3.59, credible interval [CrI] 0.019-0.067, p = .0003), activation (RR 2.39, CrI 0.048-0.125, p = .003), sedation (RR 1.94, CrI 0.035-0.157, p = .002), insomnia (RR 1.93, CrI 0.040-0.149, p = .001), abdominal pain (RR 1.53, CrI 0.032-0.164, p = .005), and headache (RR 1.24, CrI 0.003-0.139, p = .04). Activation was more common with SSRIs (versus SNRIs, RR 1.32, CrI 0.018-0.114, p = .007). Neither SSRIs nor SNRIs were associated with treatment-emergent suicidality. CONCLUSION: In pediatric OCD and anxiety disorders, SSRIs (compared with placebo) are associated with distinct AEs and greater AE-related discontinuation, although their tolerability does not differ between anxiety disorders and OCD. Compared with SNRIs, SSRIs are more likely to produce activation. Class-related AEs are important for clinicians to consider, particularly in light of data suggesting differences in class-related efficacy. Whereas SSRIs are superior to SNRIs and the treatment of choice for anxiety, for youths who become activated on SSRIs, SNRIs might represent a good second choice given their reported efficacy and lower risk of activation.
OBJECTIVE: To compare adverse events (AEs), suicidality, and AE-related discontinuation in double-blind, placebo-controlled trials of pediatric patients with obsessive-compulsive disorder (OCD) and anxiety disorders treated with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). METHOD: MEDLINE, PubMed, Web of Science, PsycINFO, and Embase were searched for peer-reviewed, English-language articles from inception through March 1, 2019. We identified prospective, randomized SSRI and SNRI studies in patients <18 years of age with OCD or generalized, separation, or social anxiety disorders. AE rates were extracted and medication-placebo differences were examined using Bayesian hierarchical models, then posterior estimates of relative risk (RR) were determined for each AE by medication class and disorder. RESULTS: Data were included from 18 trials (2,631 patients) and 7 medications (16 SSRI and 4 SNRI trials). Compared with placebo, SSRIs were associated with a greater likelihood of AE-related discontinuation (RR 3.59, credible interval [CrI] 0.019-0.067, p = .0003), activation (RR 2.39, CrI 0.048-0.125, p = .003), sedation (RR 1.94, CrI 0.035-0.157, p = .002), insomnia (RR 1.93, CrI 0.040-0.149, p = .001), abdominal pain (RR 1.53, CrI 0.032-0.164, p = .005), and headache (RR 1.24, CrI 0.003-0.139, p = .04). Activation was more common with SSRIs (versus SNRIs, RR 1.32, CrI 0.018-0.114, p = .007). Neither SSRIs nor SNRIs were associated with treatment-emergent suicidality. CONCLUSION: In pediatric OCD and anxiety disorders, SSRIs (compared with placebo) are associated with distinct AEs and greater AE-related discontinuation, although their tolerability does not differ between anxiety disorders and OCD. Compared with SNRIs, SSRIs are more likely to produce activation. Class-related AEs are important for clinicians to consider, particularly in light of data suggesting differences in class-related efficacy. Whereas SSRIs are superior to SNRIs and the treatment of choice for anxiety, for youths who become activated on SSRIs, SNRIs might represent a good second choice given their reported efficacy and lower risk of activation.
Authors: Sarah A Crawley; Nicole E Caporino; Boris Birmaher; Golda Ginsburg; John Piacentini; Anne Marie Albano; Joel Sherrill; Dara Sakolsky; Scott N Compton; Moira Rynn; James McCracken; Elizabeth Gosch; Courtney Keeton; John March; John T Walkup; Philip C Kendall Journal: Child Psychiatry Hum Dev Date: 2014-08
Authors: John S March; A Richard Entusah; Moira Rynn; Anne Marie Albano; Karen A Tourian Journal: Biol Psychiatry Date: 2007-06-05 Impact factor: 13.382
Authors: Jeffrey R Strawn; Scott T Aaronson; Ahmed Z Elmaadawi; G Randolph Schrodt; Richard C Holbert; Sarah Verdoliva; Karen Heart; Mark A Demitrack; Paul E Croarkin Journal: J Child Adolesc Psychopharmacol Date: 2020-04-21 Impact factor: 2.576
Authors: Sarah A Mossman; Jeffrey A Mills; John T Walkup; Jeffrey R Strawn Journal: J Child Adolesc Psychopharmacol Date: 2021-04-21 Impact factor: 3.031
Authors: Lu Lu; Jeffrey A Mills; Hailong Li; Heidi K Schroeder; Sarah A Mossman; Sara T Varney; Kim M Cecil; Xiaoqi Huang; Qiyong Gong; Laura B Ramsey; Melissa P DelBello; John A Sweeney; Jeffrey R Strawn Journal: J Am Acad Child Adolesc Psychiatry Date: 2021-02-04 Impact factor: 13.113
Authors: Jenny W Sun; Sonia Hernández-Díaz; Sebastien Haneuse; Florence T Bourgeois; Seanna M Vine; Mark Olfson; Brian T Bateman; Krista F Huybrechts Journal: JAMA Psychiatry Date: 2021-01-01 Impact factor: 21.596